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Background
AOCS commenced in 2000 as a collaborative study
between researchers at the Peter MacCallum Cancer
Centre (PMCC), Queensland Institute for Medical
Research (QIMR), Westmead Institute for Cancer
Research (WICR) and University of Melbourne. Patient
recruitment ceased on June 30, 2006. AOCS recruited a
total of 1834 women with invasive or borderline ovarian
cancer, far exceeding the initial target. We have received
a total of 1815 completed questionnaires and have col-
lected 1080 fresh tumour tissue samples and 1582 blood
samples. Control recruitment is also complete and a
total of 1066 control women that did not have ovarian
cancer were recruited. Clinical details have been
recorded for all AOCS patients, with clinical follow-up
done at 6-monthly intervals: we have primary treatment
data, including surgery and chemotherapy details on
99% of cases; and 89% of eligible cases have follow-up
to five years post-diagnosis.. Thus far only 123 patients
(6.5%) have been lost to follow-up, despite that fact that
30-40% of our patients return to regional areas for
ongoing treatment.
Relapse disease and collection of ascites
We are collecting ascites and tumour tissue (excess to
diagnostic requirements) from women who present with
recurrent disease. To date we have collected 337 ascitic
fluid samples from 214 patients, with scientific analysis
of these cases currently underway.
AOCS resource
AOCS is a resource for both local and international
researchers who can apply to access biospecimens and
associated data. Materials available include DNA
( t u m o u ra n dg e r m l i n e ) ,R N A ,p lasma, serum, fresh fro-
zen tissue, formalin-fixed paraffin embedded (FFPE)
blocks, Tissue Microarrays (TMA) and extensive clinical
and epidemiological data. To date we have approved
approximately 70 national and international projects and
collaborations, some of which are listed below-
￿ SWI/SNF mutations in clear cell carcinoma (BC
Cancer Agency, Vancouver, Canada)
￿ International Cancer Genomics Consortium Study
(PMCC, Melbourne, Aus)
￿ HER2 overexpression and amplification is present in
a subset of ovarian mucinous carcinomas and can be
targeted with trastuzumab therapy (University of British
Columbia, Vancouver, Canada)
￿ Genetic relationships between breast and ovarian
cancer: shared chromosomal alterations and response to
chemotherapy (Dana Faber Cancer Institute, Boston,
USA)
￿ Quality of life among women with platinum-resistant
and platinum-sensitive ovarian cancer who were treated
for recurrence: A prospective study (QIMR, Brisbane,
Aus)
￿ Development of a novel xenograft mouse model of
high grade epithelial ovarian cancer for analysis of thera-
peutic manipulation in order to improve outcomes for
patients with ovarian cancer (Walter and Eliza Hall
Institute, Melbourne, Aus)
￿ Deep sequencing of 19p13 (National Cancer Insti-
tute, Maryland, USA)
Application forms and a complete list of approved
projects can be found at http://www.aocstudy.org.
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